Mostra 1 - 20 risultati di 53 ricerca 'David D Ho', tempo di risposta: 0,05s Raffina i risultati
  1. 1
    A shot in the arm for AIDS vaccine research.

    A shot in the arm for AIDS vaccine research. di David D Ho

    Pubblicazione 2005-02-01
    Testo
    Articolo
  2. 2
    Correction: A Shot in the Arm for AIDS Vaccine Research.

    Correction: A Shot in the Arm for AIDS Vaccine Research. di David D Ho

    Pubblicazione 2005-08-01
    Testo
    Articolo
  3. 3
    Engineering multi-specific antibodies against HIV-1

    Engineering multi-specific antibodies against HIV-1 di Neal N. Padte, Jian Yu, Yaoxing Huang, David D. Ho

    Pubblicazione 2018-08-01
    Testo
    Articolo
  4. 4
    In vivo expressed biologics for infectious disease prophylaxis: rapid delivery of DNA-based antiviral antibodies

    In vivo expressed biologics for infectious disease prophylaxis: rapid delivery of DNA-based antiviral antibodies di Chasity D. Andrews, Yaoxing Huang, David D. Ho, Rachel A. Liberatore

    Pubblicazione 2020-01-01
    Testo
    Articolo
  5. 5
    An optimized thermodynamics integration protocol for identifying beneficial mutations in antibody design

    An optimized thermodynamics integration protocol for identifying beneficial mutations in antibody design di Zizhang Sheng, Jude S. Bimela, Maple Wang, Zhiteng Li, Yicheng Guo, David D. Ho

    Pubblicazione 2023-05-01
    Testo
    Articolo
  6. 6
    Natural variation in Vif: differential impact on APOBEC3G/3F and a potential role in HIV-1 diversification.

    Natural variation in Vif: differential impact on APOBEC3G/3F and a potential role in HIV-1 diversification. di Viviana Simon, Veronique Zennou, Deya Murray, Yaoxing Huang, David D Ho, Paul D Bieniasz

    Pubblicazione 2005-09-01
    Testo
    Articolo
  7. 7
    Impaired potency of neutralizing antibodies against cell–cell fusion mediated by SARS-CoV-2

    Impaired potency of neutralizing antibodies against cell–cell fusion mediated by SARS-CoV-2 di Qian Wang, Andre Yanchen Yeh, Yicheng Guo, Hiroshi Mohri, Jian Yu, David D. Ho, Lihong Liu

    Pubblicazione 2023-12-01
    Testo
    Articolo
  8. 8
    Quantification of SARS‐CoV‐2 viral load in patients using time‐to‐results in antigen lateral flow tests

    Quantification of SARS‐CoV‐2 viral load in patients using time‐to‐results in antigen lateral flow tests di Elsa W. Braunstein, Eric Vail, David D. Ho, Lihong Liu, Hiroshi Mohri, Matthew Gayhart, Glenn D. Braunstein

    Pubblicazione 2024-02-01
    Testo
    Articolo
  9. 9
    Robust SARS-CoV-2-neutralizing antibodies sustained through 6 months post XBB.1.5 mRNA vaccine booster

    Robust SARS-CoV-2-neutralizing antibodies sustained through 6 months post XBB.1.5 mRNA vaccine booster di Qian Wang, Ian A. Mellis, Yicheng Guo, Carmen Gherasim, Riccardo Valdez, Aubree Gordon, David D. Ho, Lihong Liu

    Pubblicazione 2024-09-01
    Testo
    Articolo
  10. 10
    A recoding method to improve the humoral immune response to an HIV DNA vaccine.

    A recoding method to improve the humoral immune response to an HIV DNA vaccine. di Yaoxing Huang, Michael Krasnitz, Raul Rabadan, Daniela M Witten, Yang Song, Arnold J Levine, David D Ho, Harlan Robins

    Pubblicazione 2008-01-01
    Testo
    Articolo
  11. 11
    Functional differences among the spike glycoproteins of multiple emerging severe acute respiratory syndrome coronavirus 2 variants of concern

    Functional differences among the spike glycoproteins of multiple emerging severe acute respiratory syndrome coronavirus 2 variants of concern di Qian Wang, Manoj S. Nair, Saumya Anang, Shijian Zhang, Hanh Nguyen, Yaoxing Huang, Lihong Liu, David D. Ho, Joseph G. Sodroski

    Pubblicazione 2021-11-01
    Testo
    Articolo
  12. 12
    Functional properties of the spike glycoprotein of the emerging SARS-CoV-2 variant B.1.1.529

    Functional properties of the spike glycoprotein of the emerging SARS-CoV-2 variant B.1.1.529 di Qian Wang, Saumya Anang, Sho Iketani, Yicheng Guo, Lihong Liu, Phinikoula S. Katsamba, Lawrence Shapiro, David D. Ho, Joseph G. Sodroski

    Pubblicazione 2022-06-01
    Testo
    Articolo
  13. 13
    Immunogenicity and protective efficacy of recombinant Clostridium difficile flagellar protein FliC

    Immunogenicity and protective efficacy of recombinant Clostridium difficile flagellar protein FliC di Chandrabali Ghose, Ioannis Eugenis, Xingmin Sun, Adrianne N Edwards, Shonna M McBride, David T Pride, Ciarán P Kelly, David D Ho

    Pubblicazione 2016-01-01
    Testo
    Articolo
  14. 14
    2549 Characterizing the expression kinetics of HIV-1 envelope protein

    2549 Characterizing the expression kinetics of HIV-1 envelope protein di Djin-Ye Oh, Lihong Liu, Benjamin Trinité, En-Wei Hu-Van Wright, Vincent Sahi, Yaoxing Huang, David N. Levy, David D. Ho

    Pubblicazione 2018-06-01
    Testo
    Articolo
  15. 15
    In Vivo Production of Monoclonal Antibodies by Gene Transfer via Electroporation Protects against Lethal Influenza and Ebola Infections

    In Vivo Production of Monoclonal Antibodies by Gene Transfer via Electroporation Protects against Lethal Influenza and Ebola Infections di Chasity D. Andrews, Yang Luo, Ming Sun, Jian Yu, Arthur J. Goff, Pamela J. Glass, Neal N. Padte, Yaoxing Huang, David D. Ho

    Pubblicazione 2017-12-01
    Testo
    Articolo
  16. 16
    10E8V2.0/iMab: an engineered membrane-anchored bispecific anti-HIV antibody effective in preventing and treating HIV in humanized mice

    10E8V2.0/iMab: an engineered membrane-anchored bispecific anti-HIV antibody effective in preventing and treating HIV in humanized mice di Anastasia Lanzi, Yaoxing Huang, Jian Yu, Xin Yao, Chasity D. Andrews, Lily Tsai, Mili R. Gajjar, Michael S. Seaman, Neal N. Padte, David D. Ho

    Pubblicazione 2016-05-01
    Testo
    Articolo
  17. 17
    Viral kinetics of sequential SARS-CoV-2 infections

    Viral kinetics of sequential SARS-CoV-2 infections di Stephen M. Kissler, James A. Hay, Joseph R. Fauver, Christina Mack, Caroline G. Tai, Deverick J. Anderson, David D. Ho, Nathan D. Grubaugh, Yonatan H. Grad

    Pubblicazione 2023-10-01
    Testo
    Articolo
  18. 18
    Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors

    Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors di Sho Iketani, Farhad Forouhar, Hengrui Liu, Seo Jung Hong, Fang-Yu Lin, Manoj S. Nair, Arie Zask, Yaoxing Huang, Li Xing, Brent R. Stockwell, Alejandro Chavez, David D. Ho

    Pubblicazione 2021-04-01
    Testo
    Articolo
  19. 19
    Evolving antibody evasion and receptor affinity of the Omicron BA.2.75 sublineage of SARS-CoV-2

    Evolving antibody evasion and receptor affinity of the Omicron BA.2.75 sublineage of SARS-CoV-2 di Qian Wang, Zhiteng Li, Yicheng Guo, Ian A. Mellis, Sho Iketani, Michael Liu, Jian Yu, Riccardo Valdez, Adam S. Lauring, Zizhang Sheng, Aubree Gordon, Lihong Liu, David D. Ho

    Pubblicazione 2023-11-01
    Testo
    Articolo
  20. 20
    Author Correction: Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors

    Author Correction: Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors di Sho Iketani, Farhad Forouhar, Hengrui Liu, Seo Jung Hong, Fang-Yu Lin, Manoj S. Nair, Arie Zask, Yaoxing Huang, Li Xing, Brent R. Stockwell, Alejandro Chavez, David D. Ho

    Pubblicazione 2021-05-01
    Testo
    Articolo

Strumenti per la ricerca: